Alnylam Pharmaceuticals Inc. has the data it needs to file for supplemental approval in the US in late 2022 for Onpattro (patisiran) in the treatment of transthyretin-mediated (ATTR) amyloidosis patients with cardiomyopathy now that the Phase III APOLLO-B clinical trial has met it primary and key secondary endpoints. The data disclosed on 3 August also support the company’s plan to extend its transthyretin (TTR)-silencing RNAi therapeutic franchise into a bigger ATTR amyloidosis population.
Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results
Supplemental Onpattro US Filing Planned For Late 2022
ATTR amyloidosis patients with cardiomyopathy had statistically significant functional and quality of life improvements when treated with Onpattro (patisiran) in the Phase III APOLLO-B study.
